Anticipating a rising need for individually wrapped vial medication manufacturing, The Ritedose Corporation, Inc. (Ritedose) ...

Ritedose, a sterile contract manufacturing organisation, is expanding its manufacturing facility with a seventh ...

Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for ...

If you need financial support to pay for Ohtuvayre, or if you need help understanding your insurance coverage, help is available. For example: A program called Verona Pathway Plus is available for ...

and now Verona has revealed the drug made approximately $36 million in the final three months of 2024, off more than 16,000 prescriptions. Chief executive David Zaccardelli said Ohtuvayre was off ...

Ohtuvayre is due to launch in the US in the third quarter of this year, assisted by a $650 million debt facility that Verona agreed a few months ago to build its commercial capabilities.

The best performers in the group are the Averill funds. Averill was down 2.9 percent in March but just 0.9 percent in the ...

Verona Pharma (NASDAQ:VRNA) has seen significant stock performance following the approval of OHTUVAYRE for COPD maintenance treatment. The company’s management anticipates minimal impact from ...

Verona Pharma (NASDAQ:VRNA) has seen significant stock performance following the approval of OHTUVAYRE for COPD maintenance treatment. The company's management anticipates minimal impact from tariffs, ...